Program
islatravir
Also written as “Islatravir”, “DOR/ISL” and “ISL”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Infections, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 277 open or running | phase 3since Jan 8, 2020 | Aug 13, 2014 | Aug 10, 2027phase 2 · NCT06891066 |
| Gilead Sciences | 11 open or running | phase 2since Sep 13, 2021 | Sep 13, 2021 | none ahead |
- Named in Merck’s own pipeline as
islatravir + lenacapavir (MK-8591D)
, phase 3, as of Nov 2, 2026 (source). - Named in Merck’s own pipeline as
islatravir + ulonivirine (MK-8591B)
, phase 2, as of Nov 2, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Aug 13, 2014.
- Nov 23, 2020Phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT04644029 · 730 enrolled · United States, South Africa, Uganda
- Dec 2, 2020Phase 3 study in HIV Preexposure ProphylaxisMerck · NCT04652700 · 494 enrolled · United States, Brazil, France and more
- Sep 13, 2021Gilead Sciences's first study: phase 2 study in HIV-1 InfectionNew to Gilead SciencesGilead Sciences · NCT05052996 · 142 enrolled · United States
- Nov 2, 20212 phase 2 studies in Acquired Immunodeficiency SyndromeMerck · NCT05115838, NCT05130086
- Nov 18, 20222 phase 3 studies in HIV-1 InfectionMerck · NCT05631093, NCT05630755
- Jan 20, 2023Phase 3 study in HIV-1 InfectionMerck · NCT05705349 · 537 enrolled · United States, Argentina, Canada and more
- Mar 1, 2023Phase 3 study in HIV InfectionsMerck · NCT05766501 · 641 enrolled · United States, Argentina, Australia and more
- Sep 27, 2024Phase 1 study in HealthyMerck · NCT06619678 · 36 enrolled · United States
- Dec 2, 2024Phase 1 study in HealthyMerck · NCT06719570 · 24 enrolled · United States
- Jan 31, 2025Phase 1 study in HealthyMerck · NCT06811246 · 20 enrolled · United States
- Mar 17, 2025Phase 2 study in Acquired Immunodeficiency SyndromeMerck · NCT06891066 · 150 enrolled · United States, Australia, Puerto Rico and more
- Jul 18, 2025Phase 1 study in HealthyMerck · NCT07086079 · 12 enrolled · United States
- Dec 1, 2025Phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT07266831 · 570 planned · United States, Argentina, Canada and more
- Oct 2, 2026Phase 2 study in HIV InfectionsMerck · NCT07862569 · 45 planned
Ahead
- Aug 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeMerck · NCT06891066
- Feb 1, 2029Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeMerck · NCT07266831
- Sep 24, 2029Primary completion: phase 2 study in HIV InfectionsMerck · NCT07862569
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 28 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862569HIV Infections | 2 | Not yet recruiting | Merck | Sep 24, 2029 | 45 |
| NCT07266831Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more | 3 | Recruiting | Merck | Feb 1, 2029 | 570 |
| NCT07086079Healthy · United States | 1 | Completed | Merck | Dec 8, 2025 | 12 |
| NCT06891066Acquired Immunodeficiency Syndrome · United States, Australia, Puerto Rico and more | 2 | Active, not recruiting | Merck | Aug 10, 2027 | 150 |
| NCT06811246Healthy · United States | 1 | Completed | Merck | Jul 14, 2024 | 20 |
| NCT06719570Healthy · United States | 1 | Completed | Merck | Mar 15, 2024 | 24 |
| NCT06619678Healthy · United States | 1 | Completed | Merck | Jun 23, 2024 | 36 |
| NCT05766501HIV Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Oct 16, 2025 | 641 |
| NCT05705349HIV-1 Infection · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | Oct 13, 2025 | 537 |
| NCT05631093HIV-1 Infection · United States, Australia, Canada and more | 3 | Active, not recruiting | Merck | Oct 10, 2024 | 553 |
| NCT05630755HIV-1 Infection · United States, Australia, Chile and more | 3 | Active, not recruiting | Merck | Oct 25, 2024 | 514 |
| NCT05130086Acquired Immunodeficiency Syndrome | 2 | Withdrawn | Merck | Mar 25, 2024 | 0 |
| NCT05115838Acquired Immunodeficiency Syndrome | 2 | Withdrawn | Merck | Oct 2, 2025 | 0 |
| NCT05052996HIV-1 Infection · United States | 2 | Active, not recruiting | Gilead Sciences | Dec 19, 2023 | 142 |
| NCT04652700HIV Preexposure Prophylaxis · United States, Brazil, France and more | 3 | Terminated | Merck | Aug 4, 2023 | 494 |
| NCT04644029Acquired Immunodeficiency Syndrome · United States, South Africa, Uganda | 3 | Terminated | Merck | Jul 18, 2023 | 730 |
| NCT04568603HIV-1 Infection · United States | 1 | Completed | Merck | Jul 9, 2021 | 14 |
| NCT04564547HIV-1 Infection · United States, France, Switzerland | 2 | Completed | Merck | Jan 30, 2025 | 161 |
| NCT04515641Acquired Immunodeficiency Syndrome · United States | 1 | Completed | Merck | Sep 13, 2021 | 12 |
| NCT04303156Acquired Immunodeficiency Syndrome · United States, Germany | 1 | Completed | Merck | Oct 19, 2020 | 12 |
| NCT04295772HIV-1 Infection · United States, Italy, Russian Federation and more | 2 | Completed | Merck | Dec 21, 2021 | 42 |
| NCT04233879HIV-1 Infection · United States, Argentina, Canada and more | 3 | Completed | Merck | Nov 17, 2022 | 599 |
| NCT04233216HIV-1 Infection · United States, Australia, Canada and more | 3 | Completed | Merck | Nov 21, 2022 | 35 |
| NCT04223791HIV Infections · United States, Australia, Austria and more | 3 | Completed | Merck | Aug 26, 2021 | 643 |
| NCT04223778HIV Infections · United States, Australia, Canada and more | 3 | Completed | Merck | Sep 8, 2021 | 672 |
| NCT04003103HIV-1 Infection · United States, Israel, South Africa | 2 | Completed | Merck | Mar 18, 2022 | 242 |
| NCT03272347HIV-1 Infection · United States, Chile, France and more | 2 | Completed | Merck | Mar 8, 2021 | 123 |
| NCT02217904HIV-1 | 1 | Completed | Merck | May 11, 2017 | 30 |
How it is read
Names in the registry
- “Islatravir”, 11 entries
- “DOR/ISL”, 11 entries
- “ISL”, 5 entries
- “Islatravir (ISL)”, 1 entry
- “Doravirine/Islatravir”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 4 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Infections, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.